Under the Securities Exchange Act of 1934
(Amendment No. 8)

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

With a copy to:

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box. o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1

2

3

4

This Amendment No. 8 is being filed jointly by Golden Meditech Stem Cells (BVI) Company Limited (“GM Stem Cells”), Golden Meditech Holdings Limited (“Golden Meditech”), Bio Garden Inc. (“Bio Garden”) and Yuen Kam (“Mr. Kam”, together with GM Stem Cells, Golden Meditech and Bio Garden, the “Reporting Persons”). The Reporting Persons have entered into a joint filing agreement, dated as of April 27, 2015, a copy of which is attached here to as Exhibit 11.

This Amendment No. 8 amends and supplements (i) the statement on Schedule 13D jointly filed with the Securities and Exchange Commission (the “SEC”) on July 9, 2009 by GM Stem Cells and Golden Meditech, as previously amended and supplemented by amendments to Schedule 13D filed on June 23, 2011, September 30, 2011, April 12, 2012, May 2, 2012, October 4, 2012, July 11, 2013 and August 25, 2014 (as so amended, the “Original Schedule 13D”), and (ii) the information concerning Mr. Kam and his beneficial ownership in the Company contained in the statement on Schedule 13D jointly filed with the SEC on August 25, 2014 by Cordlife Group Limited (“Cordlife”), Magnum Opus International Holdings Limited (“Magnum”) and Mr. Kam, as previously amended and supplemented by amendments to Schedule 13D filed on October 17, 2014 and November 10, 2014 (as so amended, the “Original Kam Schedule 13D”).

Item 1.                   Security and Issuer.

Item 1 of the Original Schedule 13D is hereby amended and restated in its entirety as follows:

This Schedule 13D relates to the ordinary shares, par value US$0.0001 per share (the “Ordinary Shares”), of China Cord Blood Corporation (the “Company” or “Issuer”). The Issuer’s principal executive office is located at 48th Floor, Bank of China Tower, 1 Garden Road, Central, Hong Kong S.A.R.

Item 2.                   Identity and Background.

Item 2 of the Original Schedule 13D is hereby amended and restated in its entirety as follows:

(a) – (c) and (f)

Golden Meditech, a Cayman Islands company, is an integrated healthcare enterprise in China. Golden Meditech currently holds 100% of the total equity interest in GM Stem Cells, a British Virgin Islands company. The address of the principal business and principal office of each of GM Stem Cells and Golden Meditech is 48th Floor, Bank of China Tower, 1 Garden Road, Central, Hong Kong S.A.R.

Bio Garden is a company incorporated in the British Virgin Islands. Mr. Kam is the founder of certain discretionary trusts which own the entire issued share capital of Bio Garden. The registered office of Bio Garden is Portcullis TrustNet Chambers, PO Box 3444, Road Town, Tortola, British Virgin Islands.

The name, business address, present principal occupation and citizenship of each of the executive officers and directors of each of GM Stem Cells, Golden Meditech and Bio Garden, including Mr. Kam, are set forth in Schedule A hereto.

(d) – (e)

During the past five years, none of the Reporting Persons nor, to the best knowledge of each of the Reporting Persons, any of the persons listed on Schedule A hereto has (i) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

5

Item 3.                   Source and Amount of Funds or Other Consideration.

Item 3 of the Original Schedule 13D is hereby amended and supplemented by adding the following at the end thereof:

It is currently anticipated that, at the price per Ordinary Share set forth in the Proposal (as defined in Item 4 below), approximately US$316 million will be expended in acquiring all of the outstanding Ordinary Shares of the Company not already owned by Golden Meditech. This amount excludes (i) the funds which may be required to acquire all of the 7% senior convertible notes of the Company, (ii) the funds which may be required to pay for certain outstanding restricted share units issued by the Company, and (iii) the costs and expenses associated with the Transaction (as defined below). It is anticipated that the Transaction will be financed with a combination of available cash resources and debt and equity capital.

In order to fund the Transaction, Golden Meditech proposes to conduct a conditional open offer on a fully-underwritten basis (the “Open Offer”), on the basis of one new ordinary share of Golden Meditech (the “Offer Share”) for every two existing ordinary shares of Golden Meditech to eligible shareholders of Golden Meditech with excess application at a proposed subscription price of approximately HK$1.40 per Offer Share.

On April 27, 2015, Golden Meditech and Bio Garden entered into a term sheet (the “Term Sheet”) relating to the Open Offer. Pursuant to the Term Sheet, subject to Bio Garden having obtained, on or before May 31, 2015, a credit facility from a financial institution in Hong Kong for the purposes of fully underwriting all of the Offer Shares to be issued under the Open Offer, the parties will enter into a legally binding conditional underwriting agreement setting out the terms and conditions of the underwriting arrangement described above. Such underwriting agreement must provide that Bio Garden’s obligation to underwrite the Open Offer is conditional upon, inter alia, Bio Garden having applied for, and obtained, a whitewash waiver under the Hong Kong Code on Takeovers and Mergers from the Executive Director of The Securities and Futures Commission of Hong Kong from the obligation to make a mandatory general offer for the securities of Golden Meditech not already owned or agreed to be acquired by itself or parties acting in concert with it.

The description of the Term Sheet in this Item 3 is qualified in its entirety by reference to the complete text of the Term Sheet, a copy of which is attached hereto as Exhibit 13 and is incorporated by reference in its entirety into this Item 3.

Item 4.                   Purpose of Transaction.

Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following at the end thereof:

On April 27, 2015, Golden Meditech submitted a preliminary, non-binding proposal letter (the “Proposal”) to the Company’s board of directors (the “Board”) in connection with the acquisition of all of the outstanding Ordinary Shares that are not already directly or indirectly owned by Golden Meditech (the “Transaction”). In the Proposal, Golden Meditech, among other things, indicated that (i) it is interested only in pursuing the Transaction and is not interested in selling its Ordinary Shares in any other transaction involving the Company, and (ii) it intends to acquire all of the 7% senior convertible notes of the Company.

The description of the Proposal in this Item 4 is qualified in its entirety by reference to the complete text of the Proposal, a copy of which is attached hereto as Exhibit 12 and is incorporated by reference in its entirety into this Item 4.

6

If the Transaction is carried out and consummated, the Ordinary Shares will no longer be traded on the New York Stock Exchange and the Company’s obligation to file periodic reports under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) would be terminated. In addition, consummation of the Transaction could result in one or more of the actions specified in clauses (a) - (j) of Item 4 of Schedule 13D, including the acquisition or disposition of securities of the Company, a merger or other extraordinary transaction involving the Company, a change to the Board (as the surviving company in the merger), and a change in the Company’s memorandum and articles of association to reflect that the Company would become a privately held company. No assurance can be given that any proposal, any definitive agreement or any transaction relating to the Transaction will be entered into or be consummated. The Proposal provides that no binding obligation on the part of the Company or Golden Meditech shall arise with respect to the Transaction unless and until definitive agreements have been executed.

The Reporting Persons reserve their right to change their plans and intentions in connection with any of the actions discussed in this Item 4 including among others, the purchase price for the Transaction and the debt and/or equity financing arrangements. Any action taken by the Reporting Persons may be effected at any time or from time to time, subject to any applicable limitations imposed thereon by any applicable laws.

Except as set forth in this Item 4, none of the Reporting Persons or, to the best knowledge of each of the Reporting Persons, any of the persons listed on Schedule A hereto, has any plans or proposals which relate to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons may, at any time and from time to time, formulate other purposes, plans or proposals regarding the Company, or any other actions that could involve one or more of the types of transactions or have one or more of the results described in paragraphs (a) through (j) of Item 4 of Schedule 13D.

Item 5.                   Interest in Securities of the Issuer.

Item 5 of the Original Schedule 13D is hereby amended and restated in its entirety to read as follows:

(a) - (b) The following table sets forth the beneficial ownership of Ordinary Shares of the Company for each of the Reporting Persons as of the date of this Amendment No. 8.

(1) As disclosed in the Form 20-F of the Company filed with the SEC on July 31, 2014, the Company had 73,003,248 Ordinary Shares outstanding as of March 31, 2014. In addition, as disclosed in the Schedule 13D filed with the SEC by Magnum Opus International (PTC) Limited on February 10, 2015, the Company issued an additional 7,080,000 Ordinary Shares on December 15, 2014 pursuant to its restricted share unit scheme.

(2) Includes 30,681,266 Ordinary Shares held by GM Stem Cells.

7

(3) Includes 7,137,807 of the 30,681,266 Ordinary Shares beneficially owned by Golden Meditech. Bio Garden beneficially owns 23.264385% of the ordinary shares of Golden Meditech assuming the exercise of vested warrants held by Bio Garden to purchase additional ordinary shares of Golden Meditech.

(4) Includes (i) 357,331 Ordinary Shares held by Mr. Kam, (ii) 7,165,500 of the 30,681,266 Ordinary Shares beneficially owned by Golden Meditech, and (iii) 8,809,020 Ordinary Shares issuable upon conversion in full of the Magnum Note (as defined below in Item 6) held by Magnum, a company wholly owned by Mr. Kam. Mr. Kam may be deemed to have beneficial ownership of 23.354644% of the ordinary shares of Golden Meditech assuming the exercise of vested share options held by Mr. Kam and warrants held by Bio Garden to purchase additional ordinary shares of Golden Meditech.

Mr. Kam Yu Kong currently owns 282,193 Ordinary Shares and Ms. Ting Zheng currently owns 1,071,994 Ordinary Shares. Except as disclosed in this Schedule 13D, to the best knowledge of each of the Reporting Persons, none of the persons listed on Schedule A hereto beneficially owns any Ordinary Shares.

Due to the nature of the transactions described in Item 4, the Reporting Persons may be deemed to be part of a “group” (within the meaning of Section 13(d)(3) of the Exchange Act) with each other. Except as disclosed in this Schedule 13D, each Reporting Person hereby expressly disclaims beneficial ownership of any Ordinary Shares beneficially owned by any of the other Reporting Persons or any other person, and does not affirm membership in a “group” (within the meaning of Rule 13(d)-5 of the Exchange Act) with any of the other Reporting Persons or any other person.

(c) Except as disclosed in this Schedule 13D, none of the Reporting Persons or, to the best knowledge of each Reporting Person, any of the persons listed on Schedule A hereto has effected any transaction in the Ordinary Shares during the past 60 days.

(d) Except as disclosed in this Schedule 13D, no other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the Ordinary Shares beneficially owned by the Reporting Persons, or to the best knowledge of each of the Reporting Persons, beneficially owned by the persons listed on Schedule A hereto.

(e) Not applicable.

Item 6.                   Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

Item 6 of the Original Schedule 13D is hereby amended and supplemented by adding the following at the end thereof:

The description of the Term Sheet in Item 3 and the Proposal in Item 4 is incorporated herein by reference in its entirety.

Magnum is a company wholly owned by Mr. Kam. As disclosed in the Original Kam Schedule 13D, Magnum currently holds a 7% senior convertible note due 2017 in the principal amount of US$25 million issued by the Company (the “Magnum Note”). The conversion price under the Magnum Note is US$2.838, and accordingly, subject to the terms and conditions of the Magnum Note, Magnum is entitled to receive 8,809,020 Ordinary Shares upon conversion of such note in full. The funds paid by Magnum in connection with its purchase of the Magnum Note from Golden Meditech were provided pursuant to a facility agreement between Cordlife and Magnum. Magnum also entered into a security agreement and an accounts charge with Cordlife, pursuant to which, among other things, Magnum pledged to Cordlife and granted to Cordlife a security interest in all of Magnum’s right, title and interest in, to and under (i) the Magnum Note (including all rights to payment thereunder), and (ii) any shares, or other equity securities acquired by Magnum pursuant to the Magnum Note and any other assets issued on account of such converted securities. Magnum also became a party to a registration rights agreement relating to the Ordinary Shares by and among Golden Meditech, Cordlife and the Company. For a detailed description of the Magnum Note and the other documents described above, please refer to the Original Kam Schedule 13D and the relevant exhibits thereto.

8

Item 7.                   Material to Be Filed as Exhibits.

Item 7 of the Original Schedule 13D is hereby amended and supplemented by adding the following at the end thereof:

The following documents are filed as exhibits:

9

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: April 27, 2015

10

SCHEDULE A

Additional Information Concerning Reporting Persons

The following is a list of all executive officers and directors of each of GM Stem Cells, Golden Meditech and Bio Garden and certain other information with respect to each executive officer and director.

Executive Officers and Directors of GM Stem Cells

Executive Officers and Directors of Golden Meditech

11

Executive Officers and Directors of Bio Garden

12

Exhibit 11

Joint Filing Agreement

In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13D referred to below) on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the ordinary shares, par value US$0.0001 per share, of China Cord Blood Corporation, and that this agreement may be included as an exhibit to such joint filing. This agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

[Remainder of this page has been left intentionally blank.]

IN WITNESS WHEREOF, the undersigned hereby execute this agreement as of April 27, 2015.

Exhibit 12

PROPOSAL LETTER

GOLDEN MEDITECH HOLDINGS LIMITED

April 27, 2015

The Board of Directors
China Cord Blood Corporation

48/F Bank of China Tower

1 Garden Road, Central

Hong Kong S.A.R

Dear Sirs:

Golden Meditech Holdings Limited, a company incorporated under the laws of the Cayman Islands (“Golden Meditech”), is pleased to submit this preliminary non-binding proposal to acquire all of the outstanding shares of China Cord Blood Corporation (the “Company”) not already owned by us in a going private transaction (the “Acquisition”).

We are prepared to offer US$6.40 in cash per share for each outstanding ordinary share of the Company that is not already directly or indirectly owned by Golden Meditech, subject to certain conditions as discussed below. We believe our proposal provides an attractive opportunity for the Company’s shareholders. Our proposal represents a premium of 7.18% to the volume-weighted average closing share price during the last 30 trading days, a premium of 10.63% to the volume-weighted average closing share price during the last 60 trading days and a premium of 12.80% to the volume-weighted average closing share price during the last 90 trading days.

The terms and conditions upon which we are prepared to pursue the Acquisition are set forth below. We are confident that the Acquisition can be completed on the basis outlined in this letter.

1.             Buyer.  We intend to form an acquisition vehicle for the purpose of implementing the Acquisition. The Acquisition will be in the form of a merger of the Company with the acquisition vehicle. We are interested only in pursuing the Acquisition and are not interested in selling our shares in any other transaction involving the Company.

2.             Purchase Price.  The purchase price payable for each ordinary share will be US$6.40 in cash, other than for shares held directly or indirectly by us that will be rolled over to the surviving company of the Acquisition.

3.             Convertible Notes.  In connection with the Acquisition, we also intend to acquire all of the 7% senior convertible notes of the Company pursuant to the terms and conditions of such convertible notes.

1

4.             Funding.  We intend to finance the Acquisition using a combination of available cash resources and debt and equity capital.

5.             Due Diligence.  We have engaged Shearman & Sterling LLP as our U.S. legal counsel to assist our work. We are in a position to commence customary business, financial and legal due diligence on the Company immediately, and we expect to be able to complete due diligence on a highly expedited basis, and are prepared and ready to engage in the next stage of discussions in parallel with our diligence exercise.

6.             Definitive Agreements.  We are prepared to promptly negotiate and finalize mutually satisfactory definitive agreements with respect to the Acquisition and related transactions (the “Definitive Agreements”). The Definitive Agreements will provide for representations, warranties, covenants and conditions which are typical, customary and appropriate for transactions of this type.

7.             Process.  We recognize that the Company’s Board of Directors will need to evaluate the Acquisition independently before it can make a determination to endorse it. This proposal has been approved by the Board of Directors of Golden Meditech. The approval of Golden Meditech’s shareholders will also be required in connection with the Acquisition.

8.             Confidentiality.  We are sure you will agree that it is in all of our interests to proceed in a confidential manner, unless otherwise required by law, rules, codes and regulations (including regulations of the relevant securities exchanges), until we have executed the Definitive Agreements or terminated our discussions.

9.             No Binding Commitment.  This letter constitutes only a preliminary indication of our interest, and does not constitute an offer capable of acceptance or a binding commitment with respect to the Acquisition. Such a commitment will result only from the execution of the Definitive Agreements, and then will be on the terms provided in such documentation.

In closing, we would like to express our commitment to working with you to bring the Acquisition to a successful and timely completion. Should you have any questions regarding this proposal, please do not hesitate to contact us. We look forward to hearing from you.

2

[Proposal Letter Signature Page]

Exhibit 13

Date: 27 April 2015

TERM SHEET

relating to underwriting for an Open Offer of Golden Meditech Holdings Limited

Golden Meditech Holdings Limited

AND

Bio Garden Inc.

Details

Parties

Background

A                                    The Company is a company incorporated in the Cayman Islands with limited liability and whose shares are listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”). The Company, together with its subsidiaries (collectively, the “Group”), is a leading provider of integrated healthcare services and medical devices.

B                                    China Cord Blood Corporation (“CO”), a company incorporated in the Cayman Islands with limited liability and whose shares are listed on the New York Stock Exchange, Inc., is a non-wholly-owned subsidiary of the Company and one of the principal contributors of revenue and profit to the Group.

C                                    The Company proposes to acquire all of the ordinary shares of CO which are not already directly or indirectly owned by the Company (the “Acquisition”).  A letter in connection with the proposed Acquisition has been delivered to the board of directors of CO.

D                                    As of the date of this term sheet (this “Term Sheet”), Bio Garden owns 370,650,000 ordinary shares of HK$0.20 each in the capital of the Company (each, a “Share”), representing approximately 20.62% of the issued share capital of the Company. Mr. Kam Yuen, chairman and an executive director of the Company, is the founder of certain discretionary trusts which own the entire issued share capital of Bio Garden.

E                                     In order to fund the Acquisition, the Company proposes to conduct a conditional open offer on a fully-underwritten basis (the “Open Offer”), on the basis of one new ordinary Share (the “Offer Share”) for every two existing Shares to eligible shareholders of the Company with excess application at a proposed subscription price of approximately HK$1.40 per Offer Share (the “Offer Price”). On the assumption that there will be 1,797,874,481 Shares outstanding on the relevant record date for the proposed Open Offer, the funds to be raised through the Proposed Open Offer will reach approximately HK$1,259 million.

F                                      At the request of the Company, Bio Garden has agreed, subject to financing, to enter into a legally binding conditional underwriting agreement in respect of the proposed Open Offer. The parties herein wish to state their agreement in this Term Sheet.

Term Sheet

1.                                   Underwriting

1.1                            The purpose of this Term Sheet is to confirm that, subject to Bio Garden having obtained, on or before 31 May 2015, sufficient and irrevocable credit facility from a financial institution in Hong Kong (the “Facility”) for the purposes of fully underwriting all of the Offer Shares to be issued under the Open Offer of the Company at the Offer Price for each Offer Share (the “Underwriting Arrangement”), the parties will enter into a legally binding conditional underwriting agreement (the “Underwriting Agreement”) setting out the terms and conditions of the Underwriting Arrangement.

1.2                         The Underwriting Agreement must provide that Bio Garden’s obligation to underwrite the Open Offer is conditional upon, inter alia, Bio Garden having applied for, and obtained, a whitewash waiver under The Code of Takeovers and Mergers from the Executive Director of The Securities and Futures Commission of Hong Kong from the obligation to make a mandatory general offer for the securities of the Company not already owned or agreed to be acquired by itself or parties acting in concert with it.

1.3                            The conditions set out in clauses 1.1 and 1.2 may not be waived by either party.

2.                                   Underwriting Agreement

2.1                            The parties agree to negotiate in good faith the terms and conditions of the Underwriting Agreement as soon as practicable prior to the fulfilment of the conditions set out in clause 1.1 and 1.2.

2.2                            In consideration of the Underwriting Arrangement, an underwriting commission amounting to HK$9,500,000 shall be payable by the Company to Bio Garden as the sole underwriter to the Open Offer.

3.                                   Consent on Announcement

Bio Garden acknowledges and agrees that the Company and CO may make public disclosure (including in the form of an announcement, public statement or media release) of the contents of this Term Sheet, whether or not pursuant to laws, regulations, codes or rules of the relevant securities exchanges.

4.                                   Governing Law

This Term Sheet shall be governed by the laws of Hong Kong Special Administrative Region of the People’s Republic of China.

5.                                   Counterparts

This Term Sheet may be executed in counterparts.  All counterparts together will be taken to constitute one instrument.

2

Signing page

EXECUTED by the authorized representatives of the parties hereto as of the day and year first above written.

3